The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
Open accessAbstract
Retinal gene therapy is increasingly recognized as a novel molecular intervention that has huge potential in treating common causes of blindness, the majority of which have a genetic aetiology1–5. Choroideremia is a chronic X-linked retinal degeneration that was first described in 18726. It leads to progressive blindness due to deficiency of Rab-escort protein 1 (REP1). We designed an adeno-associated viral vector to express REP1 and assessed it in a gene therapy clinical trial by subretinal injection in 14 patients with choroideremia. The primary endpoint was vision change in treated eyes 2 years after surgery compared to unoperated fellow eyes. Despite complications in two patients, visual acuity improved in the 14 treated eyes over controls (median 4.5 letter gain, versus 1.5 letter loss, P = 0.04), with 6 treated eyes gaining more than one line of vision (>5 letters). The results suggest that retinal gene therapy can sustain and improve visual acuity in a cohort of predominantly late-stage choroideremia patients in whom rapid visual acuity loss would ordinarily be predicted. The long-term follow-up results of a phase 1/2 retinal gene therapy clinical trial for choroideremia (NCT01461213) support the safety and efficacy of the treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the adoption of foot pedal-controlled viscous fluid injection systems has greatly improved injection pressure control during subretinal injection (Fischer et al., 2016; Xue et al., 2018).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Xue et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, subretinal gene therapy appears to induce NAb formation only infrequently in clinical trials and pre-clinical studies (Rakoczy et al., 2015; Reichel et al., 2018; Xue et al., 2018; Fischer et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Xue et al., 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [9]
In the citing paper
“A phase I/II clinical trial of subretinal gene therapy using an AAV2 vector to deliver human REP1 to the outer retina has shown sustained preservation or improvement of visual acuity over 2 to 5 years in patients with advanced disease [MacLaren 2014, Xue 2018].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as Xue 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,651
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Self-citationRetinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337
Self-citationCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Clinical Characteristics and Current Therapies for Inherited Retinal DegenerationsPreprint
Sahel, J., Marazova, K., & Audo, I. S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 249
Ghazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., et al. (2016) · Human Genetics · doi:10.1007/s00439-016-1637-y · Cited by 243
Research works printed but not linked: 1
- Mauthner, L. Ein Fall von Choroideremia. Berl. Natur-med. Ver Innsbruck 2, 191 (1872).
Cited by
Sorted by citations
Items 101–185 of 185
Poli, F. E., Yusuf, I. H., Jolly, J. K., Taylor, L. J., Adeyoju, D., Josan, A. S., Birtel, J., Issa, P. C., Cehajic‐Kapetanovic, J., da Cruz, L., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.9.24 · Cited by 10
Self-citationMacLaren, R. E., Lam, B. L., Fischer, M. D., Holz, F. G., Pennesi, M. E., Birch, D. G., Sankila, E., Meunier, I., Stepien, K. E., Sallum, J. M. F., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.01.022 · Cited by 10
Self-citationCehajic‐Kapetanovic, J., Jasani, K., Shanks, M. E., Clouston, P., & MacLaren, R. E. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1755985 · Cited by 10
Self-citationMandal, N., & Lotery, A. J. (2019) · Eye · doi:10.1038/s41433-019-0348-8 · Cited by 10
Self-citationProteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina
Ding, K., Shen, J., Hackett, S. F., Khan, M., & Campochiaro, P. A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00233-1 · Cited by 9
Bellingrath, J.-S., McClements, M. E., Kaukonen, M. K., Fischer, M. D., & MacLaren, R. E. (2021) · Genes · doi:10.3390/genes12121908 · Cited by 9
Self-citationJolly, J. K., Couldridge, C., Xue, K., & MacLaren, R. E. (2019) · Ophthalmologica · doi:10.1159/000503294 · Cited by 8
Self-citationPrecision Medicine Trials in Retinal Degenerations
Levi, S. R., Ryu, J., Liu, P., & Tsang, S. H. (2021) · Annual Review of Vision Science · doi:10.1146/annurev-vision-100419-111701 · Cited by 8
Bilateral visual acuity decline in males with choroideremia: a pooled, cross-sectional meta-analysis
Bozkaya, D., Zou, H., Lu, C., Tsao, N., & Lam, B. L. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02250-z · Cited by 8
Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency
Fry, L. E., Peddle, C. F., Stevanovic, M., Barnard, A. R., McClements, M. E., & MacLaren, R. E. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0021 · Cited by 10
Self-citationTHE PROGRESSION OF MACULAR STRUCTURAL AND FUNCTIONAL CHANGES IN LATE-ONSET RETINAL DEGENERATION
Papastavrou, V. T., O’Brien, J. M., Regan, A. J., Aftab, A. M., & Browning, A. C. (2020) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001067 · Cited by 7
MERTK missense variants in three patients with retinitis pigmentosa
Poli, F. E., Yusuf, I. H., Clouston, P., Shanks, M. E., Whitfield, J., Issa, P. C., & MacLaren, R. E. (2022) · Ophthalmic Genetics · doi:10.1080/13816810.2022.2113541 · Cited by 7
Self-citationA Quantitative Chloride Channel Conductance Assay for Efficacy Testing of AAV.BEST1
Wood, S., McClements, M. E., de la Cámara, C. M.-F., Patrício, M. I., Uggenti, C., Sekaran, S., Barnard, A. R., Manson, F. D. C., & MacLaren, R. E. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.267 · Cited by 7
Self-citationOxidative and Endoplasmic Reticulum Stress Represent Novel Therapeutic Targets for Choroideremia
Sarkar, H., Lahne, M., Nair, N., & Moosajee, M. (2023) · Antioxidants · doi:10.3390/antiox12091694 · Cited by 6
Intraoperative OCT-Guided Volumetric Measurements of Subretinal Therapy Delivery in Humans
Valikodath, N. G., Li, J. D., Raynor, W., Izatt, J. A., Toth, C. A., & Vajzovic, L. M. (2024) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264241253920 · Cited by 6
Greig, L. C., Gutierrez, K. G., Oh, J. K., Levi, S. R., Korot, E., Tsang, S. H., & Mahajan, V. B. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101543 · Cited by 6
Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
Han, R. C., Fry, L. E., Kantor, A., McClements, M. E., Xue, K., & MacLaren, R. E. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1882300 · Cited by 6
Self-citationAn optometrist’s guide to the top candidate inherited retinal diseases for gene therapy
O’Hare, F., Edwards, T. L., Hu, M. L., Hickey, D. G., Britten‐Jones, A. C., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1878851 · Cited by 6
Self-citationCorrecting visual loss by genetics and prosthetics
Xue, K., & MacLaren, R. E. (2020) · Current Opinion in Physiology · doi:10.1016/j.cophys.2020.03.003 · Cited by 5
Self-citationA novel robot-assisted subretinal injection system: preliminary validation in ex vivo porcine eyes
Wang, Q., Zhao, L., Wang, C., He, Q., Xu, N., Yang, K., Li, N., Liu, M., Zhang, H., & Wang, L. (2025) · Journal of Robotic Surgery · doi:10.1007/s11701-025-02521-z · Cited by 5
Using Goldmann Visual Field Volume to Track Disease Progression in Choroideremia
DeLuca, A. P., Whitmore, S. S., Tatro, N. J., Andorf, J. L., Faga, B. P., Faga, L. A., Collins, M. M., Luse, M. A., Fenner, B. J., Stone, E. M., et al. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100397 · Cited by 5
Gene Augmentation of CHM Using Non-Viral Episomal Vectors in Models of Choroideremia
Toualbi, L., Toms, M., Almeida, P. V., Harbottle, R. P., & Moosajee, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015225 · Cited by 5
Precision Therapy for Inherited Retinal Disease
Koulisis, N., & Nagiel, A. (2020) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2020.02.007 · Cited by 5
Gao, F., Tian, G., Hu, F., Wang, D., Li, J., Chang, Q., Chen, F., Xu, G., Liu, W., & Wu, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01478-x · Cited by 5
NIHR Ophthalmology Specialty Group, Dawson, S. R., Linton, E., Beicher, K., Gale, R. P., Patel, P. J., Ghanchi, F. D., Beresford, M. W., Poustie, V., Chakravarthy, U., et al. (2018) · Eye · doi:10.1038/s41433-018-0251-8 · Cited by 5
Quantification of RPE Changes in Choroideremia Using a Photoshop-Based Method
Zhai, Y., Xu, M., Dimopoulos, I. S., Birch, D. G., Bernstein, P. S., Holt, J., Kirn, D. H., Francis, P. J., & MacDonald, I. M. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.21 · Cited by 5
Choroideremia: Toward Regulatory Approval of Retinal Gene TherapyPreprint
Yusuf, I. H., & MacLaren, R. E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041279 · Cited by 5
Self-citationRetinal Patterns and the Role of Autofluorescence in Choroideremia
Poli, F. E., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Genes · doi:10.3390/genes15111471 · Cited by 4
Self-citationBerger, A., Johnson, C. D., Marmorstein, A. D., & Scruggs, B. A. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14593 · Cited by 5
Xu, Y., Liu, X., Wu, N., Long, Y., Ren, J., Wang, Y., Su, X., Liu, Z., Fujinami‐Yokokawa, Y., Fujinami, K., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.13.27 · Cited by 4
Ranked Importance of Visual Function Outcome Measures in Choroideremia Clinical Trials
Josan, A. S., Taylor, L. J., Xue, K., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.13.58 · Cited by 4
Self-citationSuárez-Herrera, N., Riswick, I. B., Vázquez-Domínguez, I., Duijkers, L., Karjosukarso, D. W., Piccolo, D., Bauwens, M., Baere, E. B. W. D., Cheetham, M. E., Garanto, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.019 · Cited by 4
Wood, L. J., Jolly, J. K., Groppe, M., Benjamin, L., Kirwan, J., Patel, N., Elgohary, M. A., & MacLaren, R. E. (2020) · Clinical ophthalmology · doi:10.2147/opth.s254532 · Cited by 4
Self-citationEmerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease
Burgess, F. R., Hall, H. N., & Megaw, R. D. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000545 · Cited by 4
Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date
Kalatzis, V., Roux, A., & Meunier, I. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00558-y · Cited by 4
Sub-Retinal Delivery of Human Embryonic Stem Cell Derived Photoreceptor Progenitors in rd10 Mice
Tun, S. B. B., Shepherdson, E., Tay, H. G., & Barathi, V. A. (2023) · Journal of Visualized Experiments · doi:10.3791/65848 · Cited by 3
Schlemm's canal-selective Tie2/TEK knockdown induces sustained ocular hypertension in adult mice
Schwakopf, J., Romero, C. O., López, N. N., Millar, J. C., Vetter, M. L., & Bosco, A. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110114 · Cited by 3
Ahmad, A., Mandwie, M., O’Sullivan, K. M., Smyth, C. M., York, J., Doyle, H. J., Holdsworth, S. R., Pickering, M. C., Lachmann, P. J., Alexander, I. E., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.264 · Cited by 3
Zhang, H., Yin, S., Guan, N., Wang, J., Cheng, Q., Zhang, L., Zheng, Q., Lv, H., & Wei, W. (2025) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2024-001908 · Cited by 2
Directional Analysis of Residual RPE Area Loss in the Natural History of Choroideremia
Chujo, S., Abbasgholizadeh, R., Alhelaly, M., Nittala, M. G., Quarta, A., Chung, Y.-C., Kwak, H., Soylu, C., Rattu, R., Huang, J., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.6.23 · Cited by 2
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Ansari, G., Giudici, N. L., Cancian, G., Rossouw, P., Rui, C., Rosso, A., Gazzina, S., Feltgen, N., Pfau, K., & Pfau, M. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100886 · Cited by 2
Stem Cell and Gene Therapy for Inherited Retinal Diseases
DeSouza, P. J., Park, U. C., & Park, S. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_3 · Cited by 2
Bozesan, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-54016-6_1 · Cited by 2
Yerxa, B. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819291-7.00006-x · Cited by 2
Measuring X inactivation skew for retinal diseases with adaptive nanopore sequencingPreprint
Gocuk, S. A., Lancaster, J., Su, S., Jolly, J. K., Edwards, T. L., Hickey, D. G., Ritchie, M. E., Blewitt, M. E., Ayton, L. N., & Gouil, Q. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.20.585856 · Cited by 2
Self-citationReichel, F. F., Király, P., Seitz, I. P., & Fischer, M. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073705 · Cited by 1
Afridi, R., Halim, M. S., Ahmed, M., Yucel, H., Fazal, Z. Z., Janjua, K., Campigotto, M., Shah, S. M., Nguyen, Q. D., & Sepah, Y. J. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.12.20 · Cited by 1
Quantification of Ocular Gene Therapy–Related Inflammation Using the VRMACS Grading System
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101316 · Cited by 1
Self-citationPrecision Is Not Enough: When Tools Outpace Translation in Ocular Gene Therapy
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Genes · doi:10.3390/genes17030283 · Cited by 1
Self-citationChen, K.-Y., Chan, H.-C., & Chan, C.-M. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103923 · Cited by 1
Tolmachov, O. E. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109328 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Microperimetry in Children’s Practice
Khubieva, R. R. (2021) · Ophthalmology in Russia · doi:10.18008/1816-5095-2021-4-807-814 · Cited by 1
Choroideremia and Other Hereditary Conditions Manifesting with Choroidal Atrophy
Song, W. K., Cehajic‐Kapetanovic, J., Patrício, M. I., Xue, K., & MacLaren, R. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_4 · Cited by 1
Self-citationGene therapies for retinal dystrophies: potential in the Chinese population
Kwok, A. K. H., & Wong, H. L. (2022) · Hong Kong Journal of Ophthalmology · doi:10.12809/hkjo-v26n1-324 · Cited by 1
Hassall, M., & Simunovic, M. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_35 · Cited by 1
Inherited Retinal Degenerations in the Pediatric Population
Lorenz, B., & Preising, M. N. (2021) · Springer eBooks · doi:10.1007/978-981-15-6552-6_24 · Cited by 1
Choroideremia and Other Hereditary Conditions Manifesting with Choroidal Atrophy
Song, W. K., Cehajic‐Kapetanovic, J., Patrício, M. I., Xue, K., & MacLaren, R. E. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_4-1 · Cited by 1
Self-citationNanoparticles as Cell Tracking Agents in Human Ocular Cell Transplantation Therapy
Mundy, D. C., & Goldberg, J. L. (2021) · Current Ophthalmology Reports · doi:10.1007/s40135-021-00275-z · Cited by 1
Gene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease
Simunovic, M. P., Mack, H. G., Ayton, L. N., & Hassall, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00154-7 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Der natürliche Verlauf der Choroideremie
Seitz, I. P., & Fischer, M. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0841-3417
Gentherapie in der Pädiatrie – bereits Realität oder noch immer Fiktion?
Bartholdi, D. (2019) · Pädiatrie up2date · doi:10.1055/s-0043-115206
Hereditary Retinal Diseases: Stargardt, Choroideremia, Retinitis Pigmentosa
Dysli, C., Solberg, Y., & Sauer, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-22878-1_15
Gene Therapy for Inherited Retinal Disease
Dharmaraj, S. (2021) · Springer eBooks · doi:10.1007/978-981-33-4168-5_34
Innate Immunity and the Retinal Pigment Epithelium in Gene Therapy for Inherited Retinal Disorders
Casey, G. A. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-px5t-6n74
Genetic disorders causing non-syndromic retinopathy
(2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00013-5
Gene therapy and treatment trials
MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00008-1
Self-citationImmunological and Inflammatory Side Effects of Treatments for Age-Related Macular Degeneration
Chiang, T.-K., Kurup, S. K., & Hariprasad, S. M. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230724-01
Gene Therapy Trial on X-Linked Retinitis Pigmentosa Caused by Mutations in RPGR
de la Cámara, C. M.-F., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_17
Self-citationTam, L. C. S., Joel, J., Stampoulis, D., Little, A., Walton, A., Atkinson-Dell, R., Devine, M., Hill, J., Esteve-Rudd, J., & Ellis, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4636180/v1
Okur, N. Ü., Okur, M. E., Bülbül, E. Ö., Miliotou, Α. N., Karantas, I. D., & Siafaka, P. I. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128373593250619074556
Shen, L. L., Zhang, Y., Wong, J., Foote, K. G., Porco, T. C., Wang, R. K., Roorda, A., & Duncan, J. L. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.40
One down but many more to go: the state of gene therapy for inherited retinal disease
Tan, T., Sun, C., Poh, S. S. J., Lim, J., Teo, J. X. J., Dey, S., Chua, Z., Guo, J., Wang, Z., Tay, H. G., et al. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2571360
Gao, F., 田国红, Hu, F.-Y., Wang, D.-D., Li, J.-K., Chang, Q., Chen, F., Xu, G.-Z., Liu, W., & Wu, J.-H. (2020) · Figshare · doi:10.6084/m9.figshare.12414587
Gao, F., 田国红, Hu, F.-Y., Wang, D.-D., Li, J.-K., Chang, Q., Chen, F., Xu, G.-Z., Liu, W., & Wu, J.-H. (2020) · Figshare · doi:10.6084/m9.figshare.12414596
John, M. C., de la Cámara, C. M.-F., Salman, A., Staurenghi, F., Shamsnajafabadi, H., McClements, M. E., Cehajic‐Kapetanovic, J., Bray, A., Fischer, M. D., Dick, A. D., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201652
Self-citationGene therapy in ophthalmology: new prospects
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Фаисович, А. Р., & Rizvanov, A. A. (2026) · Kazan medical journal · doi:10.17816/kmj677044
Buonocore, S., Giamundo, G., Barone, C., Carratù, I., Trinchese, G., Vitale, G. A., Fasciolo, G., Ziaco, M., Venditti, P., Fontana, A., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08592-6
Cone Contrast and Entropy of Adaptive Optics Images in Choroideremia
Huang, A. M., Xu, P., Cooper, R. F., & Morgan, J. I. W. (2026) · Current Eye Research · doi:10.1080/02713683.2026.2645894
Owliaee, I., Teimoori, A., Shoushtari, M., & Shojaeian, A. (2026) · Clinical ophthalmology · doi:10.2147/opth.s593854
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Gene therapy in patients with choroideremia: a meta-analysis of clinical trials
Guerrero, P. R., Ridruejo-Ortega, B., González-Barros, D., Silva-Schultz, S., Stalmashka, T., Molinero-Sicilia, L., Benites, G., Rivera‐Izquierdo, M., Usategui-Martín, R., & Pastor‐Idoate, S. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07326-w
Oliani, C., Coelho, G. L., Barboza, M. N. C., & Bermudes, F. H. (2026) · Revista Brasileira de Oftalmologia · doi:10.37039/1982.8551.20260087
Metadata
- Authors
- Xue, K., Jolly, J. K., Barnard, A. R., Rudenko, A., Salvetti, A. P., Patrício, M. I., Edwards, T. L., Groppe, M., Orlans, H. O., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., Downes, S. M., Seabra, M. C., & MacLaren, R. E.
- Affiliations
- University of Oxford (GB)
- Oxford University Hospitals NHS Trust (GB)
- Imperial College London (GB)
- St Mary's Hospital (GB)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Southampton (GB)
- University College London (GB)
- Corresponding author
- MacLaren, Robert E.
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-10
- Volume
- 24
- Issue
- 10
- Pages
- 1507-1512
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7032956
- OpenAlex
- W2893026352
- Semantic Scholar
- c5ea88dabcecb2c7d2fa7f60b4ea7a8e431e29d4
- Cited by
- 185
- References
- 36
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 21 · 2023: 17 · 2022: 23 · 2021: 40 · 2020: 34 · 2019: 26 · 2018: 1
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (091984)
- National Institute for Health and Care Research (NF-SI-0515-10020, HICF-1009-006, NF-SI-0515-10047, CL-2014-13-003, ICA-CDRF-2016-02-002)
- Royal College of Surgeons of Edinburgh
- University College London
- University of Oxford
- Oxford University Hospitals NHS Foundation Trust
- Moorfields Eye Hospital NHS Foundation Trust
- Medical Research Council (MR/N00101X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, Rab escort protein 1, REP1, adeno-associated virus vectors, subretinal injection, visual acuity, X-linked retinal degeneration, gene therapy clinical trials, visual outcome
- MeSH terms
- Dependovirus, Adult, Aged, Genetic Vectors, Humans, Male, Middle Aged, Retina, Retinal Degeneration, Vision, Ocular, Visual Acuity, Genetic Therapy, Choroideremia, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
